Previous Close | 13.86 |
Open | 13.87 |
Bid | 14.35 x 100 |
Ask | 14.52 x 300 |
Day's Range | 13.71 - 14.91 |
52 Week Range | 4.51 - 15.00 |
Volume | |
Avg. Volume | 152,950 |
Market Cap | 589.673M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
AbbVie (ABBV) inks an option-to-license and collaboration deal with Gilgamesh to develop next-generation therapies for psychiatric disorders.
Natalie Holles, Chief Executive Officer of Third Harmonic Bio Inc (NASDAQ:THRD), sold 20,222 shares of the company on May 9, 2024.
Natalie Holles, CEO of Third Harmonic Bio Inc (NASDAQ:THRD), has sold 13,558 shares of the company on April 11, 2024, according to a recent SEC Filing.